S-570
S-570 is an orally active selective STING antagonist. S-570 inhibits the secretion of the cytokines IFN-β and IL-6. S-570 can be used for research on inflammation.
For research use only. We do not sell to patients.
- CAS No.: 2718206-92-7
- Formula: C17H12ClF3N4
- Molecular Weight:364.75
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
IL-6 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
0.041 μM
|
Inhibition of human STING in human IRF-reporter HEK293 cells overexpressing human STING assessed as reduction in reporter activity by dose-response curve analysis.
Inhibition of human STING in human IRF-reporter HEK293 cells overexpressing human STING assessed as reduction in reporter activity by dose-response curve analysis.
|
42562155 |
| THP-1 | IC50 |
0.018 μM
|
Inhibition of IFN-β secretion in 2′,3′-cGAMP-stimulated human monocyte THP-1 cells assessed by dose-response curve analysis.
Inhibition of IFN-β secretion in 2′,3′-cGAMP-stimulated human monocyte THP-1 cells assessed by dose-response curve analysis.
|
42562155 |
| B16 | IC50 |
0.071 μM
|
Antagonist activity against mouse STING in CMA-stimulated mouse B16 cells assessed as reduction in reporter activity by dose-response curve analysis.
Antagonist activity against mouse STING in CMA-stimulated mouse B16 cells assessed as reduction in reporter activity by dose-response curve analysis.
|
42562155 |
In Vitro
S-570 is a potent hSTING antagonist in HEK293 cells with an IC50 of 0.041 μM[1].
S-570 potently inhibits IFN-β secretion in 2′,3′-cGAMP (HY-100564)-stimulated THP-1 cells with an IC50 of 0.018 μM[1].
S-570 (30 min) exhibits improved stability in liver microsomes, with 44.1% remaining after 30 min[1].
S-570 is a potent mouse STING antagonist in mouse B16 cells with an IC50 of 0.071 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice[1]
-
Dosage:1, 3, 10, 30 mg/kg
-
Administration:p.o.
-
Result:Suppressed plasma levels of IFN-β, IL-6, and TNF-α in a dose-dependent manner.
Chemical Information
-
CAS No. 2718206-92-7
-
Molecular Weight 364.75
-
Formula C17H12ClF3N4
-
SMILES
CN1C2=CC=C(C(F)(F)F)C=C2N=C1NC3=CNC4=C3C=C(Cl)C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)